Genentech's Giredestrant Plus Everolimus Cuts Risk Of Progression Or Death 44% In ITT And 62% In ESR1-Mutated ER-Positive Advanced Breast Cancer In Phase III EvERA; FDA Goal Dates Are Dec. 18 For Advanced Disease And Nov. 30 For Early-Stage Disease

Genentech's Giredestrant combined with everolimus has demonstrated a 44% reduction in the risk of disease progression or death in the intent-to-treat population and a 62% reduction in patients with ESR1 mutations, compared to standard treatment. This combination aims to address resistance to endocrine therapies and enhance patient outcomes. The FDA has set a goal date for the approval of Giredestrant for early-stage breast cancer on November 30, 2026, and for advanced disease on December 18, 2026.